Sitagliptin: 7 agencies, 2007–2021
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 14.1 years separate the first record, 5 Jun 2007 at TLV (Sweden), from the most recent, 21 Jul 2021 at HAS (France).
TLV (Sweden) changed its position: recommended on 5 Jun 2007, restricted by 2 Dec 2009.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
Nothing has been added since 2021; on this evidence the file is dormant.
The programme is broad: 11 distinct indication wordings are recorded for sitagliptin by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 29 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
TLV (Sweden) was first to assess sitagliptin, on 5 Jun 2007; PHARMAC (New Zealand) did not open a file until 21 Feb 2019 — an unusually long tail of 11.7 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 8 years in total.
6 of the 7 agencies here assessed sitagliptin more than once, HAS (France) most often at 12 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for sitagliptin.
The full ledger for sitagliptin reads 11 other, 8 recommended, 5 not assessed and 2 restricted, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 21 Jul 2021 | Re-assessment of SMR and ASMR | SMR moderate · ASMR V | source |
| PHARMAC (New Zealand) | 21 Feb 2019 | Diabetes - type 2 | PTAC advice: No Formal Recommendation · decision reached | source |
| G-BA (Germany) | 15 Dec 2016 | Xelevia — benefit assessment §35a | added benefit: not proven | source |
| PBAC (Australia) | 2015 | Type 2 diabetes mellitus (in combination with insulin) | The PBAC rejected the request to list sitagliptin, sitagliptin+metformin and sitagliptin+m… | source |
| SMC (Scotland) | 8 Oct 2007 | Type 2 diabetes | accepted (restricted) | source |
24 further decisions for sitagliptin, across 6 agencies, are not shown here. They link to 14 further source documents.
Related molecules
- empagliflozin — same ATC class A10B — Diabetes
- dapagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- metformin / sitagliptin — same ATC class A10B — Diabetes
- liraglutide — same ATC class A10B — Diabetes
- tirzepatide — same ATC class A10B — Diabetes
Coverage: 29 decisions for sitagliptin from 7 agencies, 2007 to 2021. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.